Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
75.88%
Operating Margin
127.24%
Net Margin
78.47%
Efficiency Metrics
Revenue per Expense Ratio
28,970,367.0
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
127.24%
Income Tax Rate
0.00%
EPS
0.6000000000
Balance Sheet Analysis
Current Ratio
0.57
Cash Ratio
0.13
Working Capital
$-20.29M
Debt to Equity
0.55
Debt to Assets
32.72%
Equity Ratio
59.67%
Cash Flow Analysis
Operating Cash Flow Ratio
173.58%
Free Cash Flow Ratio
173.58%
CapEx to Revenue
0.00%
Dividends Paid
$54.53M
Stock Buybacks
$66.75K
Total Shareholder Returns
$54.60M
Cash Position Change
-44.32%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
142.24%
Net Income
132.88%
EPS
132.61%
Operating Income
156.56%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
2.37%
Operating Cash Flow
-66.97%
Free Cash Flow
-66.97%
Balance Sheet Health
Assets
-5.92%
Debt
-2.69%
Book Value per Share
-6.53%
Inventory
-24.63%
Shareholder Returns
Dividends per Share
-1.04%
Shares Outstanding
0.85%
Long Term Trends
3Y Revenue/Share
-59.42%
5Y Revenue/Share
179.06%
3Y Dividend/Share
-3.01%
5Y Dividend/Share
-10.73%